Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Description:
Host: Joyce O'Shaughnessy, MD
Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an...